Roivant Sciences Presents at Jefferies Global Healthcare Conference 2026: CEO Matthew Gline Discusses Late-Stage Pipeline and Upcoming Commercial Launches.

Roivant Sciences, a $20 billion market cap company, is presenting at the Jefferies Global Healthcare Conference 2026. CEO Matthew Gline discusses the company's late-stage pipeline, including brepocitinib, IMVT-1402, and mosliciguat, all of which appear to be drugs that matter. Roivant is preparing for its first major commercial launch, brepocitinib in dermatomyositis, expected by the end of September, with more data coming later this year.

Roivant Sciences Ltd. (Nasdaq: ROIV), a biopharmaceutical company with a market capitalization of approximately $20 billion, is set to present at the Jefferies Global Healthcare Conference 2026. During the presentation, CEO Matthew Gline is expected to highlight the company’s late-stage pipeline, which includes three key therapeutic candidates: brepocitinib, IMVT-1402, and mosliciguat. These programs represent significant milestones in Roivant’s strategy to develop and commercialize innovative treatments for autoimmune and pulmonary diseases with high unmet medical needs.

The company is preparing for its first major commercial launch with brepocitinib, a dual selective inhibitor of TYK2 and JAK1, for the treatment of dermatomyositis (DM). Roivant announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for brepocitinib and granted it Priority Review, with a Prescription Drug User Fee Act (PDUFA) target action date set for the third quarter of 2026. If approved, brepocitinib would be the first targeted therapy approved for DM, a rare autoimmune condition with limited treatment options. The company expects to launch the drug in the United States by the end of September 2026, pending regulatory clearance.

The NDA filing for brepocitinib in DM was supported by positive results from the Phase 3 VALOR trial, which demonstrated statistically significant and clinically meaningful improvements in disease activity compared to placebo. The trial enrolled 241 patients and showed that brepocitinib 30 mg achieved a mean Total Improvement Score (TIS) of 46.5 at week 52, compared to 31.2 for placebo (p=0.0006). The drug also demonstrated a favorable safety profile consistent with previous trials.

In addition to brepocitinib, Roivant is advancing IMVT-1402, a monoclonal antibody targeting the neonatal Fc receptor (FcRn), in multiple autoimmune indications, including rheumatoid arthritis and Graves’ disease. The company has also initiated a Phase 2 trial for mosliciguat, an inhaled soluble guanylate cyclase (sGC) activator, in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). Mosliciguat has shown promising results in early trials, including a 38% reduction in pulmonary vascular resistance in PH patients.

Looking ahead, Roivant has outlined an ambitious development and commercialization timeline, with multiple pivotal trials and regulatory milestones expected over the next 12 to 18 months. The company’s strategic focus on clinical execution and pipeline advancement positions it to potentially deliver several transformative therapies across autoimmune and pulmonary disease areas.